Gyre Therapeutics, Inc. — Revenue by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8a15d60e-293b-47a4-89c0-7a91d6ede62a/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $116.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-106251 |
| FY 2024 | $105.8M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-040279 |
| FY 2023 | $113.5M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-037242 |
| FY 2022 | $102.3M | 2022-01-01 – 2022-12-31 | evidence 0000950170-24-037242 |
| FY 2021 | $7.3M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-012877 |
| FY 2020 | $20.9M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-010823 |
| FY 2018 | $6.0k | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006879 |
| FY 2017 | $1.0M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-006879 |
| FY 2014 | $275.0k | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-093871 |
| FY 2013 | $3.6M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-099974 |
| FY 2012 | $57.9M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-109464 |
| FY 2011 | $97.6M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-099259 |
| FY 2010 | $85.7M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-099259 |
| FY 2009 | $25.1M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-099259 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Gyre Therapeutics, Inc. — all facts · Net Income · Operating Income